YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease

BACKGROUND Disease-modifying therapies for Alzheimer's disease (AD) would be most effective during the preclinical stage (pathology present, cognition intact) before significant neuronal loss occurs. Therefore, biomarkers that detect AD pathology in its early stages and predict dementia onset and progression will be invaluable for patient care and efficient clinical trial design. METHODS AD-associated changes in cerebrospinal fluid (CSF) were measured using two-dimensional difference gel electrophoresis and liquid chromatography tandem mass spectrometry. Subsequently, CSF YKL-40 was measured by enzyme-linked immunosorbent assay in the discovery cohort (n = 47), validation cohort (n = 292) with paired plasma samples (n = 237), frontotemporal lobar degeneration (n=9) [corrected], and progressive supranuclear palsy (PSP; n = 6). Immunohistochemistry was performed to identify source(s) of YKL-40 in human AD brain. RESULTS Discovery and validation cohorts, showed higher mean CSF YKL-40 in very mild and mild AD-type dementia (Clinical Dementia Rating [CDR] 0.5 and 1) versus control subjects (CDR 0) and PSP subjects. Importantly, CSF YKL-40/Aβ42 ratio predicted risk of developing cognitive impairment (CDR 0 to CDR > 0 conversion), as well as the best CSF biomarkers identified to date, tau/Aβ42 and p-tau 181/Aβ42. Mean plasma YKL-40 was higher in CDR 0.5 and 1 versus CDR 0, and correlated with CSF levels. YKL-40 immunoreactivity labeled astrocytes near a subset of amyloid plaques, implicating YKL-40 in the neuroinflammatory response to Aβ deposition. CONCLUSIONS These data demonstrate that YKL-40, a putative indicator of neuroinflammation, is elevated in AD and, together with Aβ42, has potential prognostic utility as a biomarker for preclinical AD.

[1]  A. Fagan,et al.  APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging , 2010, Annals of neurology.

[2]  A. Starkey,et al.  In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases , 2010, Journal of Neuroinflammation.

[3]  K. Blennow,et al.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. , 1999, Archives of neurology.

[4]  P. Kiener,et al.  YKL-40 Is Elevated in Patients with Chronic Obstructive Pulmonary Disease and Activates Alveolar Macrophages1 , 2008, The Journal of Immunology.

[5]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[6]  Andrew D Rowan,et al.  The Mammalian Chitinase-like Lectin, YKL-40, Binds Specifically to Type I Collagen and Modulates the Rate of Type I Collagen Fibril Formation* , 2006, Journal of Biological Chemistry.

[7]  R. Martins,et al.  A4 amyloid protein deposition and the diagnosis of Alzheimer's disease , 1988, Neurology.

[8]  H. Kleinman,et al.  Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. , 1999, Experimental cell research.

[9]  David M Holtzman,et al.  Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease , 2007, Proteomics. Clinical applications.

[10]  H. Ling,et al.  Inflammatory Cytokines Induce Production of CHI3L1 by Articular Chondrocytes* , 2005, Journal of Biological Chemistry.

[11]  Gina N. LaRossa,et al.  [11C]PIB in a nondemented population , 2006, Neurology.

[12]  K. Blennow,et al.  Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. , 2007, Journal of Alzheimer's disease : JAD.

[13]  J. Lundgren,et al.  YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Purulent Meningitis , 2002, Clinical and Vaccine Immunology.

[14]  J. Johansen.  Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. , 2006, Danish medical bulletin.

[15]  D. Mash,et al.  Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. , 1998, Journal of neuropathology and experimental neurology.

[16]  G. Meyer,et al.  Neurons in the White Matter of the Adult Human Neocortex , 2009, Front. Neuroanat..

[17]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[18]  Tony Wyss-Coray,et al.  Inflammation in Neurodegenerative Disease—A Double-Edged Sword , 2002, Neuron.

[19]  M. Hallett,et al.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.

[20]  J. Morris,et al.  Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage alzheimer’s disease , 2001, Journal of Molecular Neuroscience.

[21]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[22]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[23]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[24]  I. Sokal,et al.  CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment , 2007, Neurology.

[25]  A. J. Millis,et al.  gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. , 2003, Experimental cell research.

[26]  S. Younkin,et al.  An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. , 1994, Science.

[27]  James P. Malone,et al.  Comparative Proteomic Analysis of Intra- and Interindividual Variation in Human Cerebrospinal Fluid*S , 2005, Molecular & Cellular Proteomics.

[28]  J Philip Miller,et al.  Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI , 2006, Neurology.

[29]  Brian,et al.  Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. , 1993, The Journal of biological chemistry.

[30]  A. Fagan,et al.  Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease , 2009, EMBO molecular medicine.

[31]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[32]  C. Colton,et al.  Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD , 2006, Journal of Neuroinflammation.

[33]  H. Ling,et al.  The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. , 2002, The Biochemical journal.

[34]  H. Ling,et al.  The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. , 2004, The Biochemical journal.

[35]  S. Henriksen,et al.  Induction of pathogenic sets of genes in macrophages and neurons in NeuroAIDS. , 2003, The American journal of pathology.

[36]  T. Tanriverdi,et al.  Elevated cerebrospinal fluid and serum YKL-40 levels are not associated with symptomatic vasospasm in patients with aneurysmal subarachnoid haemorrhage , 2008, Journal of Clinical Neuroscience.

[37]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[38]  À. Rovira,et al.  Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. , 2010, Brain : a journal of neurology.

[39]  F. De Ceuninck,et al.  YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. , 2001, Biochemical and biophysical research communications.

[40]  N. Schultz,et al.  Plasma YKL-40: a potential new cancer biomarker? , 2009, Future oncology.

[41]  A. Fagan,et al.  Multimodal techniques for diagnosis and prognosis of Alzheimer's disease , 2009, Nature.

[42]  J. Mellors,et al.  YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. , 2008, The American journal of pathology.

[43]  Trey Sunderland,et al.  Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. , 2003, JAMA.

[44]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[45]  R. Flavell,et al.  Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13–induced tissue responses and apoptosis , 2009, The Journal of experimental medicine.

[46]  A. Fagan,et al.  Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. , 2009, Archives of neurology.

[47]  M. Freedman,et al.  Frontotemporal lobar degeneration , 1998, Neurology.

[48]  David M. Holtzman,et al.  Biomarkers of Alzheimer's disease , 2009, Neurobiology of Disease.

[49]  Michael T. Heneka,et al.  Inflammatory processes in Alzheimer's disease , 2007, Journal of Neuroimmunology.